Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) insider Camille Bedrosian sold 10,028 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $32.40, for a total transaction of $324,907.20. Following the sale, the insider directly owned 278,064 shares in the company, valued at approximately $9,009,273.60. This represents a 3.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Amylyx Pharmaceuticals Price Performance
Amylyx Pharmaceuticals stock traded up $2.02 during mid-day trading on Monday, reaching $33.64. The company had a trading volume of 1,816,910 shares, compared to its average volume of 1,682,389. Amylyx Pharmaceuticals, Inc. has a 1 year low of $10.83 and a 1 year high of $41.14. The company has a market capitalization of $3.75 billion, a P/E ratio of -23.52 and a beta of -0.13. The stock’s 50-day simple moving average is $25.69 and its 200-day simple moving average is $18.87.
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, equities analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several analysts have weighed in on AMLX shares. Citigroup upped their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Mizuho lifted their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Guggenheim raised their target price on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Finally, HC Wainwright upped their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $36.50.
Get Our Latest Report on Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Company Profile
Read More
- Five stocks we like better than Amylyx Pharmaceuticals
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
